Home

HROW

Harrow, Inc.

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

$38.23

-2.10%

2026-05-08

About Harrow, Inc.

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

Key Fundamentals

Forward P/E

14.26

EPS (TTM)

$-0.14

ROE

-8.5%

Revenue Growth (YoY)

33.3%

Profit Margin

-1.9%

Debt/Equity

483.72

Price/Book

27.54

Beta

0.34

Market Cap

$1.45B

Avg Volume (10D)

511K

Recent Breakout Signals

Near-Breakout WatchD1
2026-02-24
Near-Breakout WatchD1
2026-01-06
Momentum BreakoutD1
2026-01-05
Near-Breakout WatchD1
2024-12-03
Momentum BreakoutD1
2024-08-08
Near-Breakout WatchD1
2024-07-22
Momentum BreakoutD1
2023-06-21
Near-Breakout WatchD1
2023-06-15
Momentum BreakoutD1
2023-06-01
Near-Breakout WatchD1
2023-05-31

Recent Price Range (60 Days)

60D High

$54.49

60D Low

$33.03

Avg Volume

686K

Latest Close

$38.23

Get breakout alerts for HROW

Sign up for Breakout Scanner to receive daily notifications when HROW triggers breakout signals. Build custom AI screeners and backtest strategies.

Start Free Trial

7-day free trial. No card required.

Harrow, Inc. (HROW) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors HROW daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. HROW operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.